Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000899243-18-027169
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-22 16:33:49
Reporting Period:
2018-10-18
Accepted Time:
2018-10-22 16:33:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1305253 Eiger Biopharmaceuticals Inc. EIGR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207833 L Arnold Oronsky 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
1276600 Khaled Nasr 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
1293171 H Gilbert Kliman 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
1443898 Interwest Partners X Lp 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
1460207 Interwest Management Partners X, Llc 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
1553019 Keval Desai 2710 Sand Hill Road, Suite 200
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-10-18 210,800 $12.07 1,388,792 No 4 S Direct
Common Stock Disposition 2018-10-18 26,465 $12.00 1,362,327 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.30 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  2. Price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was $12.00 to $12.03 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. These securities are held of record by InterWest Partners X, L.P. ("IW10"). InterWest Management Partners X, LLC ("IMP10") is the general partner of IW10 and has sole voting and investment control over the shares owned by IW10. Gilbert H. Kliman, and Arnold L. Oronsky are Managing Directors of IMP10 and, Keval Desai and Khaled A. Nasr, are Venture Members of IMP10. All Reporting Persons disclaim beneficial ownership of shares of Eiger BioPharmaceuticals, Inc. stock held by IW10, except to the extent of their respective pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1944, or otherwise, any of the Reporting Persons are the beneficial owner of all of the equity securities covered by this statement.